Wednesday, February 26, 2025

#USA, #Texas announces first #death in #measles #outbreak

The Texas Department of State Health Services is reporting the first death from measles in the ongoing outbreak in the South Plains and Panhandle regions. 

The school-aged child who was not vaccinated was hospitalized in Lubbock last week and tested positive for measles.

As of Feb. 25, 124 cases of measles have been confirmed in the outbreak since late January. Most of the cases are in children. Eighteen people have been hospitalized over the course of the outbreak.

Measles is a highly contagious respiratory illness, which can cause life-threatening illness to anyone who is not protected against the virus. During a measles outbreak, about one in five people who get sick will need hospital care and one in 20 will develop pneumonia. Rarely, measles can lead to swelling of the brain and death. It can also cause pregnancy complications, such as premature birth and babies with low birth weight.

Measles can be transmitted by direct contact with infectious droplets or by airborne spread when an infected person breathes, coughs, or sneezes. People who are infected will begin to have symptoms within a week or two after being exposed. Early symptoms include high fever, cough, runny nose, and red, watery eyes. A few days later, the telltale rash breaks out as flat, red spots on the face and then spreads down the neck and trunk to the rest of the body. A person is contagious about four days before the rash appears to four days after. People who could have measles should stay home during that period.

People who think they have measles or may have been exposed to measles should isolate themselves and call their health care provider before arriving to be tested. It is important to let the provider know that the patient may have measles and to get instructions on how to come to the office for diagnosis without exposing other people to the virus.

The best way to prevent getting sick is to be immunized with two doses of a measles-containing vaccine, which is primarily administered as the combination measles-mumps-rubella or MMR vaccine. Two doses of the MMR vaccine prevent more than 97 percent of measles infections. A small number of vaccinated people can occasionally develop measles. In these cases, the symptoms are generally milder, and they are less likely to spread the disease to other people. DSHS and the Centers for Disease Control and Prevention recommend children receive one dose of MMR at 12 to 15 months of age and another at 4 to 6 years. Children too young to be vaccinated are more likely to have severe complications if they get infected with the measles virus. However, each MMR dose lowers the risk of infection and the severity of illness if infected.

Health care providers can find recommendations for infection control and diagnostic testing in DSHS health alerts. Providers should report any suspected cases to their local health department immediately, preferably while the patient is still with the provider.

DSHS posts additional information about the outbreak cases on the News & Alerts page on Tuesdays and Fridays.

Source: Department of Health, https://www.dshs.texas.gov/news-alerts/texas-announces-first-death-measles-outbreak

____

#Italy - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Follow up report 17

{Excerpt, Feb. 26 2025 Update}

1) HPAI H5N1 was detected in a Yellow-legged Gull (Larus michahellis) found dead in the Municipality of Rimini, province of Rimini, Emilia Romagna region.

2) HPAI H5N1 was detected in an Eurasian buzzard (common buzzard) (Buteo buteo) found dead in the Municipality of Pramaggiore, province of Venezia, Veneto region

3) HPAI H5N1 was detected in a Eurasian buzzard (common buzzard) (Buteo buteo) found dead in the Municipality of Galzignano Terme, province of Padova, Veneto region

4) HPAI H5N1 was detected in a yellow-legged gull (Larus michahellis) found dead in the Municipality of Padova, province of Padova, Veneto region.

5) HPAI H5N1 was detected in a yellow-legged gull (Larus michahellis) found dead in the Municipality of Stanghella, province of Padova, Veneto region.

6) HPAI H5N1 was detected in a Yellow-legged Gull (Larus michahellis) found dead in the Municipality of Porto Recanati, province of Macerata, Marche region. "The Database of Global Administrative Boundaries (GADM) used by WAHIS, provides Loreto as the municipality corresponding to the given coordinates. As a matter of fact the location of the infected premises is the municipality of Porto Recanati."

7) HPAI H5N1 was detected in a black-headed gull (Chroicocephalus ridibundus) found dead in the Municipality of Ortona dei Marsi, province of L'Aquila, Abruzzo region

8) HPAI H5N1 was detected in a common shelduck (Tadorna tadorna) found dead in the municipality of Marano Ligure, province of Udine, Friuli-Venezia Giulia region. Note on 30/01/2025: The start date of the outbreak was changed from 30/11/2024 to 24/12/2024 after more precise information was received by the country.

9) HPAI H5N1 was detected in a common buzzard (Buteo buteo) found dead in the Municipality of Lignano Sabbiadoro, province of Udine, Friuli-Venezia Giulia region

10) HPAI H5N1 was detected in a gadwall (Anas strepera) found dead in the Municipality of Lignano Sabbiadoro, province of Uadova, Friuli Venezia Giulia region.

11) HPAI H5N1 was detected in a little egret (Egretta garzetta) found dead in the Municipality of Lignano Sabbiadoro, province of Udine, Friuli-Venezia Giulia region

12) HPAI H5N1 was detected in a common kingfisher (Alcedo atthis) found dead in the municipality of Trebaseleghe, province of Padova, Veneto region.

13) HPAI H5N1 was detected in a Yellow-legged Gull (Larus michahellis) found dead in the Municipality of Venezia, province of Venezia, Veneto region.

14) HPAI H5N1 was detected in a grey heron (Ardea cinerea) found dead in the Municipality of Villa del Conte, province of Padova, Veneto region

15) HPAI H5N1 was detected in an African sacred ibis (Threskiornis aethiopicus) found dead in the Municipality of San Martino Buon Albergo, province of Verona, Veneto region

16) HPAI H5N1 was detected in an African sacred ibis (Threskiornis aethiopicus) found dead in the Municipality of San Martino Buon Albergo, province of Verona, Veneto region

17) HPAI H5N1 was detected in a yellow-legged gull (Larus michahellis) found dead in the Municipality of Fontevivo, province of Parma, Emilia Romagna region.

(...)

Source: WOAH, https://wahis.woah.org/#/in-event/5912/dashboard

____

Mass #mortality #events in the sub- #Antarctic #Indian #Ocean caused by long-distance circumpolar spread of highly pathogenic avian #influenza #H5N1 clade 2.3.4.4b

Abstract

Since 2020, the outbreak of highly pathogenic avian influenza (HPAI) virus clade 2.3.4.4b has turned into the largest documented panzootic to date, reaching the sub-Antarctic region and Antarctica via the tip of South America in 2023. Here, we describe its recent arrival into the Indian Ocean sub-Antarctic archipelagos of Crozet and Kerguelen, where we first detected the virus in October 2024 in dead southern elephant seals, king penguins, gentoo penguins, brown skuas and kelp gulls. While the panzootic is ongoing, it has already caused unprecedented and alarming mortalities of southern elephant seals. We collected brain swabs from various seal and bird carcasses, subsequently isolated the virus and obtained 25 novel HPAI H5N1 clade 2.3.4.4b sequences. Our phylogenetic and phylogeographic analyses show that there have been independent introductions of the virus to Crozet and Kerguelen, from the distant South Georgia Islands in the Southern Atlantic, and not from the more nearby coasts of South Africa. Our results point to a year-long gap in genomic surveillance in the south polar region, obscuring how HPAI H5N1 clade 2.3.4.4b is spreading in the sub-Antarctic and illustrating the difficulties in tracking pathogen dispersal in the region. Locally, our phylogenetic analyses show that the virus is transmitted between different species. Moreover, our serological analyses show that some southern elephant seal pups had mounted an anti-H5 antibody response. With the spread to Crozet and Kerguelen, HPAI H5N1 2.3.4.4b is moving ever closer to Australia and New Zealand, which currently remain free from infections with this strain, and represents a major threat to the sub-Antarctic wildlife. Our results provide key elements to enable stakeholders to anticipate the arrival and spread of the virus in remote areas of critical wildlife conservation concerns.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.02.25.640068v1

____

#Cambodia confirmed a #fatal pediatric case of #H5N1 avian #influenza virus infection

{Original text in Khmer}

Ministry of Health Press Release


A Fatal Case of #H5N1 #influenza in a 2-Year-7-Month-Old Child


The Ministry of Health of the Kingdom of Cambodia wishes to inform the public that there are a case of bird flu in a 2-year-old 7-month-old child has been confirmed positive for the influenza virus H5N1 by the National Institute of Public Health on February 25, 2025.

Location: Tangak Village, Romchek Commune, Preah Sdach District, Prey Veng Province.

According to doctors, the child died on February 25, 2025 due to the parents took the child to the hospital, when him developed a serious condition, including fever, cough, fatigue, and difficulty retreating.

Severe breathing. According to the investigation, the patient's house has a family chicken farm and there are dead chickens. 

About 15 of them were sick and the children were sleeping and playing in the basement near the chicken coop.

The national and subnational emergency response teams of the Ministry of Health cooperated. With the working group of the provincial Department of Agriculture and local authorities at all levels are actively conducting research continue to try to respond to the emergence of avian influenza with technical methods and protocols.

-- Find sources of transmission in both animals and humans and continue to search for suspected cases and victims to prevent transmission

-- Distribute Tamiflu to others in the community and establish close contact.

-- Health education campaign for the people of the village where the incident occurred.

The Ministry of Health once again reminds all citizens to be careful 

-- Beware of bird flu as H5N1 bird flu continues to threaten

-- Health of our people and also ask you to inform yourself if you have fever, cough, runny nose or

-- Difficulty breathing and history of contact with sick or dead chickens during the 14 days prior to the onset date

-- Do not go to crowded or crowded cities and seek advice and counseling.

-- Get medical checkups immediately at a nearby health center or hospital to avoid procrastination.

-- High risk of eventual death.

Transmission: H5N1 bird flu is a common flu that is usually transmitted between sick birds to other birds, but can sometimes be transmitted from birds to humans through close contact with sick or dead birds.

Bird flu in humans is a serious disease that requires timely hospitalization.

Although it is not easily spread from person to person, if it manages to metabolize it, it can be as contagious as the seasonal flu.

How to prevent:

-- Do not touch or eat sick or dead chickens and wear gloves and a mask or cover your nose with a scarf beforehand

-- Grab the chicken and cook it in boiling water before plucking it.

-- Stick to the practice of washing your hands often before handling food.

-- Especially after contact ..., poultry or other objects that can be a source of infection.

-- Cook thoroughly before eating, especially poultry and eggs. Do not eat eggs Or egg yolks and keep raw and cooked foods separate, clean utensils for proper cooking.

-- If there are many sick or dead chickens in the house or village and they have fever, cough, runny nose or

-- Shortness of breath, hurry to seek advice and treatment at the health center or nearby hospitals avoid delays immediately, exposing them to greater risk

Therefore, the public should be aware and take care of their health with the above preventive methods. Health will continue to publish information related to public health issues on the official social media of the Ministry of Health, as well as the official Facebook page of the Department of Infectious Diseases and the website www.cdcmoh.gov.kh.

For more information, you can call the toll-free number 115 of the Ministry of Health Free of charge. 

Tuesday 13 Roch Khemak, Rong Chhasak, BE 2561 - Royal Decree, February 25, 2025, Kingdom of Cambodia - Ministry of Health

Source: Ministry of Health of the Kingdom of Cambodia, https://moh.gov.kh/kh/notice/detail/58

_____

Tuesday, February 25, 2025

Structural basis of #receptor-binding #adaptation of #human-infecting #H3N8 #influenza A virus

ABSTRACT

Recent avian-origin H3N8 influenza A virus (IAV) that have infected humans pose a potential public health concern. Alterations in the viral surface glycoprotein, hemagglutinin (HA), are typically required for IAVs to cross the species barrier for adaptation to a new host, but whether H3N8 has adapted to infect humans remains elusive. The observation of a degenerative codon in position 228 of HA in human H3N8 A/Henan/4-10/2022 protein sequence, which could be residue G or S, suggests a dynamic viral adaptation for human infection. Previously, we found this human-isolated virus has shown the ability to transmit between ferrets via respiratory droplets, with the HA-G228S substitution mutation emerging as a critical determinant for the airborne transmission of the virus in ferrets. Here, we investigated the receptor-binding properties of these two H3N8 HAs. Our results showed H3N8 HAs have dual receptor-binding properties with a preference for avian receptor binding, and G228S slightly increased binding to human receptors. Cryo-electron microscopy structures of the two H3N8 HAs with avian and human receptor analogs revealed the basis for dual receptor binding. Mutagenesis studies reveal that the Q226L mutation shifts H3N8 HA’s receptor preference from avian to human, while the G228S substitution enhances binding to both receptor types. H3N8 exhibits distinct antigenic sites compared to H3N2, prompting concerns regarding vaccine efficacy. These findings suggest that the current H3N8 human isolates are yet to adapt for efficient human-to-human transmission and further continuous surveillance should be implemented.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01065-24?af=R

____

#Dynamics of a #Panzootic: Genomic #Insights, #Host Range, and #Epidemiology of the Highly Pathogenic Avian #Influenza A(#H5N1) Clade 2.3.4.4b in #USA

Abstract

In late 2021, Eurasian-lineage highly pathogenic avian influenza (HPAI) A(H5N1) viruses from HA clade 2.3.4.4b were first detected in the United States. These viruses have caused severe morbidity and mortality in poultry and have been detected in numerous wild and domestic animals, including cows and humans. Notably, infected cows transmitted the virus to cats, causing extreme pathogenicity and death. While human-to-human spread of the virus has not been recorded, efficient transmission of the bovine-origin virus has also led to extreme pathogenicity and death in ferret models. Recently, markers in PB2 (E627K) and HA (E186D, Q222H), indicating mammalian adaptation mutations, were detected in an H5N1-infected patient manifesting critical illness in Canada. These, combined with instances of interspecies spread of the virus, have raised global public health concerns. This could highlight the potential for the virus to successfully adapt to mammals, posing a serious risk of a global outbreak. A One Health approach is, thereby, necessary to monitor and control the outbreak. This review aims to analyze the epidemiology, transmission, and ecological impacts of HPAI A(H5N1) clade 2.3.4.4b in the U.S., identify knowledge gaps, and inform strategies for effective outbreak management and mitigation.

Source: Viruses, https://www.mdpi.com/1999-4915/17/3/312

____

#Efficacy and #safety of #sipavibart for #prevention of #COVID19 in individuals who are immunocompromised (SUPERNOVA)...

Summary

Background

Sipavibart is an anti-spike monoclonal antibody that neutralises SARS-CoV-2 with exceptions, including Phe456Leu-containing variants (eg, KP.2* and KP.3*). This trial assessed sipavibart efficacy and safety for prevention of symptomatic COVID-19 in participants who are immunocompromised.

Methods

In this ongoing, double-blind, international, phase 3 trial, we enrolled participants who were immunocompromised and aged 12 years or older at 197 hospitals, university health centres, and clinical trial units in 18 countries. Participants were randomly allocated 1:1 to a sipavibart group (intramuscular sipavibart 300 mg on days 1 and 181) or a comparator group (tixagevimab 300 mg–cilgavimab 300 mg on day 1 and placebo on day 181 or placebo on days 1 and 181), stratified by previous COVID-19 vaccination and infection status and use of tixagevimab–cilgavimab. The primary efficacy outcomes were symptomatic COVID-19 caused by any variant or symptomatic COVID-19 caused by non-Phe456Leu-containing variants within 181 days of dosing, assessed in the SARS-CoV-2-negative set, comprising all participants without a positive RT-PCR test for SARS-CoV-2 at baseline and who received at least one trial intervention dose. Safety outcomes for adverse events were assessed 90 days following the first dose and for serious adverse events throughout the study in the safety analysis set (ie, all participants who received at least one injection of sipavibart or comparator). This study is registered with ClinicalTrials.gov, NCT05648110.

Findings

Participants were screened from March 31 to Oct 27, 2023; 3349 participants (56·8% female) were randomly assigned: 1674 to the sipavibart group (five no first dose; 1669 sipavibart) and 1675 to the comparator group (nine no first dose; 1105 tixagevimab–cilgavimab and 561 placebo). Within 181 days of dosing, 122 (7·4%) of 1649 participants in the sipavibart group and 178 (10·9%) of 1631 participants in the comparator group had symptomatic COVID-19 due to any variant (relative risk reduction [RRR] 34·9% [97·5% CI 15·0 to 50·1]; p=0·0006), 54 (3·3%) participants in the sipavibart group and 90 (5·5%) participants in the comparator group had symptomatic COVID-19 due to non-Phe456Leu-containing variants (RRR 42·9% [95% CI 19·9 to 59·3]; p=0·0012), and 47 (2·9%) participants in the sipavibart group and 64 (3·9%) participants in the comparator group had symptomatic COVID-19 due to Phe456Leu-containing variants (30·4% [–1·8 to 52·5]). Adverse events occurred in 833 (49·9%) of 1671 participants in the sipavibart group and 857 (51·5%) of 1663 participants in the comparator group within 3 months of the first dose. One COVID-19-related death occurred in the comparator group. Serious adverse events considered related to trial intervention occurred in two (0·1%) of 1671 participants in the sipavibart group and seven (0·4%) of 1663 participants in the comparator group (none fatal). No serious cardiovascular or thrombotic events were considered to be related to sipavibart.

Interpretation

The primary analysis showed efficacy and safety of sipavibart in preventing symptomatic COVID-19 in participants who are immunocompromised when susceptible (ie, non-Phe456Leu-containing) variants dominated, although no efficacy was shown against resistant (ie, Phe456Leu-containing) variants that dominate as of November, 2024.

Source: The Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00804-1/fulltext?rss=yes

____

#Exposure and #survival of wild #raptors during the 2022–2023 highly pathogenic #influenza a virus #outbreak

Abstract

The global outbreak of clade 2.3.4.4b H5N1 highly pathogenic influenza A virus (HP H5N1) has had an unprecedented impact on wild birds including raptors, but long-term population impacts have not been addressed. To determine if raptors survive infections with HP H5N1, raptors from the upper Midwest United States were serologically tested for antibodies to influenza A virus (IAV), H5 and N1. Raptors were sampled at The Raptor Center’s (University of Minnesota) wildlife rehabilitation hospital and at Hawk Ridge Bird Observatory. Samples were tested for IAV antibodies using a commercially available blocking ELISA, with positive samples tested for antibodies to H5 and N1. Antibodies to IAV were detected in 86 out of 316 individuals representing 7 species. Antibodies to H5 and N1 were detected in 60 individuals representing 6 species. Bald eagles had the highest seroprevalence with 67/97 (69.1%) seropositive for IAV and 52 of these 67 (77.6%) testing positive for antibodies to both H5 and N1. Prevalence of antibodies to IAV observed in this study was higher than reported from raptors sampled in this same region in 2012. The high prevalence of antibodies to H5 and N1 indicates a higher survival rate post-HP H5N1 infection in raptors than previously believed.

Source: Scientific Reports, https://www.nature.com/articles/s41598-025-90806-6

____

Monday, February 24, 2025

#Monkeypox Virus Occurrence in #Wastewater #Environment and Its Correlation with Incidence Cases of #Mpox: A Systematic Review and Meta-Analytic Study

Abstract

The COVID-19 pandemic has increased the interest in the use of wastewater-based surveillance (WBS) strategy for infectious disease monitoring, especially when clinical cases are underreported. The excretion of monkey virus (MPXV) in the feces of both symptomatic and preclinical individuals has further driven the interest in WBS applicability to MPXV monitoring in wastewater to support its mitigation efforts. We performed a systematic review with meta-analysis, using six databases to assess MPXV detection in wastewater. We performed a random-effects model meta-analysis to calculate the pooled prevalence at a 95% confidence interval (95% CI). Also, we carried out a subgroup analysis according to the country regions and a sensitivity analysis excluding studies classified as having a high risk of bias. The overall MPXV positivity rate in wastewater was estimated at 22% (95% CI: 14−30%; I2 = 94.8%), with more detection rate in North America (26%, 95% CI: 8–43%) compared to Europe and Asia (22%, 95% CI: 12–31%). The MPXV detection rate was significantly higher in 2022 studies (22%, 95% CI: 13–31%) compared to 2023 (19%, 95% CI: 14–25%). The real-time PCR platform significantly detected more MPXV (24%, 95% CI: 14–34%) than the digital droplet PCR-based studies (17%, 95% CI: 4–31%), which was used less frequently. Viral concentration with centrifugation procedure indicated higher detection rates (21%, 95% CI: 10–33%) than other known sample concentration protocols. Generally, MPXV detection rates in wastewater samples strongly correlate with incidence cases of mpox (range of R = 0.78–0.94; p < 0.05). Findings from this study suggest that WBS of MPXV could be employed as an epidemiological early warning tool for disease monitoring and mpox outbreak prediction similar to the clinical case-based surveillance strategies.

Source: Viruses, https://www.mdpi.com/1999-4915/17/3/308

____

The #Impact of Highly Pathogenic Avian #Influenza #H5N1 in the #USA: A Scoping #Review of Past #Detections and Present #Outbreaks

Abstract

Highly Pathogenic Avian Influenza H5N1 (HPAI H5N1) was first detected in chickens in Scottland in 1959 and has since circulated globally, causing regular outbreaks among different animal species, as well as incidental infections in humans. In this scoping review, the epidemiology and impact of HPAI H5N1 among migratory birds, poultry, and cattle in the United States were analyzed, with a particular focus on outbreaks since January 2022. Following PRISMA guidelines, a total of 27 articles were identified for this review. Publicly available data and reports from the USDA and CDC were also evaluated and summarized. The identified articles primarily included epidemiological studies of detections in wild birds, mammals, and case reports on H5N1 and transmission dynamics among cattle, with a notable absence of poultry-focused reports. Wild birds, especially migratory species, have played an important role in virus dissemination. Studies among mammals, including seals, bears, and domestic cats, along with the emerging outbreak among cattle, highlight the virus’s ability to adapt to diverse hosts, with the possibility of mammal-to-mammal transmission. Despite the low number of human infections, the zoonotic risk of the disease and the possibility of a human outbreak remain significant. The complexity and risks associated with the virus, in comparison with the limited current scientific studies in the United States, demand further investigations to mitigate its impact on animals, ecosystems, and human health.

Source: Viruses, https://www.mdpi.com/1999-4915/17/3/307

____

Highly Pathogenic Avian #Influenza A (#H5N1) Clade 2.3.2.1a virus #infection in domestic #cats, #India, 2025

Abstract

In January 2025, the highly pathogenic avian influenza A(H5N1) virus clade 2.3.2.1a infection was detected in domestic cats and whole-genome sequencing of two cat H5N1 isolates was performed using the Oxford Nanopore MinION sequencing platform. Phylogenetic analysis revealed the circulation of triple reassortant viruses in cats. Although cat viruses lacked classic mammalian adaptation markers they carried mutations associated with enhanced polymerase activity in mammalian cells and increased affinity for α2-6 sialic acid receptor suggesting their potential role in facilitating infection in cats. The identification of reassortant HPAI H5N1 clade 2.3.2.1a viruses in domestic cats in India highlights the urgent need for enhanced surveillance in domestic poultry, wild birds, and mammals, including humans, to track genomic diversity and molecular evolution of circulating strains.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.02.23.638954v1

____

Sunday, February 23, 2025

In-hospital #outcomes and 6-month follow-up results of #patients supported with #ECMO for #COVID19 from the 2nd wave to end of pandemic (EuroECMO-COVID)...

Summary

Background

Extracorporeal membrane oxygenation (ECMO) for COVID-19 was thoroughly assessed during the first pandemic wave, but data on subsequent waves are limited. We aimed to investigate in-hospital and 6-month survival of patients with COVID-19 supported with ECMO from the second pandemic wave (Sept 15, 2020) until the end of the pandemic (March 21, 2023, announced by WHO).

Methods

EuroECMO-COVID is a prospective, observational study including adults (aged ≥16 years) requiring ECMO respiratory support for COVID-19 from 98 centres in 21 countries. We compared patient characteristics and outcomes between in-hospital survivors and non-survivors. Mixed-effects multivariable logistic regressions were used to investigate factors linked to in-hospital mortality. 6-month survival and overall patient status were determined via patient contact or chart review. This study is registered with ClinicalTrials.gov, NCT04366921, and is complete.

Findings

We included 3860 patients (2687 [69·7%] were male and 1169 [30·3%] were female; median age 51 years [SD 11]) from 98 centres in 21 countries. In-hospital mortality was 55·9% (n=2158), with 81·2% (n=1752) deaths occurring during ECMO support. More non-survivors had diabetes, hypertension, cardiovascular disease, and renal failure, and required more pre-ECMO inotropes and vasopressors compared with survivors. Median support duration was 18 days (IQR 10–31) for both groups. Factors linked to in-hospital mortality included older age, pre-ECMO renal failure, pre-ECMO vasopressors use, longer time from intubation to ECMO initiation, and complications, including neurological events, sepsis, bowel ischaemia, renal failure, and bleeding. Of the 1702 (44·1%) in-hospital survivors, 99·7% (n=1697) were alive at 6 months follow-up. Many patients at 6 months follow-up had dyspnoea (501 [32·0%] of 1568 patients), cardiac (122 [7·8%] of 1568 patients), or neurocognitive (168 [10·7%] of 1567 patients) symptoms.

Interpretation

Our data for patients undergoing ECMO support for respiratory distress from the second COVID-19 wave onwards confirmed most findings from the first wave regarding patient characteristics and factors correlated to in-hospital mortality. Nevertheless, in-hospital mortality was higher than during the initial pandemic wave while 6-month post-discharge survival remained favourable (99·7%). Persisting post-discharge symptoms confirmed the need for post-ECMO patient follow-up programmes.

Source: Lancet Respiratory Medicine, https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00369-2/abstract?rss=yes

____

Structure-based #Design of Chimeric #Influenza #Hemagglutinins to Elicit Cross-group #Immunity

Abstract

Antigenic variability among influenza virus strains poses a significant challenge to developing broadly protective, long-lasting vaccines. Current annual vaccines target specific strains, requiring accurate prediction for effective neutralization. Despite sequence diversity across phylogenetic groups, the hemagglutinin (HA) head domain's structure remains highly conserved. Utilizing this conservation, we designed cross-group chimeric HAs that combine antigenic surfaces from distant strains. By structure-guided transplantation of receptor-binding site (RBS) residues, we displayed an H3 RBS on an H1 HA scaffold. These chimeric immunogens elicit cross-group polyclonal responses capable of neutralizing both base and distal strains. Additionally, the chimeras integrate heterotrimeric immunogens, enhancing modular vaccine design. This approach enables the inclusion of diverse strain segments to generate broad polyclonal responses. In the future, such modular immunogens may serve as tools for evaluating immunodominance and refining immunization strategies, offering potential to bridge and enhance immune responses in individuals with pre-existing immunity. This strategy holds promise for advancing universal influenza vaccine development.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.12.17.628867v2

____

A Vestal Virgin Crowned With Flowers, Jacques-Louis David (1783)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/jacques-louis-david/a-vestal-virgin-crowned-with-flowers

____

#Coronavirus Disease Research #References (by AMEDEO, Feb. 23 '25)


 

    Antiviral Res

  1. INOUE A, Ichikawa T, Wada D, Maruyama S, et al
    M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings.
    Antiviral Res. 2025;236:106118.
    PubMed         Abstract available

  2. ZIAN D, Iaconis D, Nenci S, Crusco A, et al
    The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis during medical emergencies: identification of effective antiviral 3CLpro inhibitors.
    Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119.
    PubMed         Abstract available


    Clin Infect Dis

  3. LUETKEMEYER AF, Chew KW, Lacey S, Hughes MD, et al
    Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
    Clin Infect Dis. 2025 Feb 17:ciaf029. doi: 10.1093.
    PubMed         Abstract available

  4. SIM BZ, Wolfe CR
    Antiviral Trials-Navigating the Shifting Sands of a Pandemic.
    Clin Infect Dis. 2025 Feb 17:ciaf031. doi: 10.1093.
    PubMed        


    Emerg Infect Dis

  5. FERREIRA FC, Pervin T, Tang WW, Hediger JA, et al
    Respiratory Shedding of Infectious SARS-CoV-2 Omicron XBB.1.41.1 Lineage among Captive White-Tailed Deer, Texas, USA.
    Emerg Infect Dis. 2025;31:267-274.
    PubMed         Abstract available

  6. DAVIES MA, de Gier B, Guy RL, Coelho J, et al
    Streptococcus pyogenes emm Type 3.93 Emergence, the Netherlands and England.
    Emerg Infect Dis. 2025;31:229-236.
    PubMed         Abstract available


    Graefes Arch Clin Exp Ophthalmol

  7. SUN M, Wu M, Zhang L, Zhou H, et al
    Clinical characteristics of optic neuritis following COVID-19 during Omicron outbreak in China.
    Graefes Arch Clin Exp Ophthalmol. 2025 Feb 21. doi: 10.1007/s00417-025-06780.
    PubMed         Abstract available


    Intensive Care Med

  8. OLMOS M, Fuentes N, Busico M, Gallardo A, et al
    Effectiveness of bundle of care on tolerance of awake-prone positioning in patients with acute respiratory failure. A multicenter observational study.
    Intensive Care Med. 2025 Feb 17. doi: 10.1007/s00134-025-07804.
    PubMed         Abstract available


    J Infect

  9. AO G, Li T, Wang Y, Balzer N, et al
    The effect of amubarvimab-romlusevimab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2025;90:106442.
    PubMed        

  10. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
    The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
    J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447.
    PubMed         Abstract available


    J Med Virol

  11. ZHANG Y, Chen H, Li Y, Luo C, et al
    Animal Models for Long COVID: Current Advances, Limitations, and Future Directions.
    J Med Virol. 2025;97:e70237.
    PubMed         Abstract available

  12. LI Y, Lu J, He L, Jiang C, et al
    Repeated Omicron Infections Overcome T Cell Immune Imprinting to Original SARS-CoV-2.
    J Med Virol. 2025;97:e70264.
    PubMed         Abstract available

  13. FRAENKEL CJ, Thuresson S, Medstrand P, Alsved M, et al
    Comparison of Airborne SARS-CoV-2 Omicron and Pre-Delta Variants Around Infected Patients.
    J Med Virol. 2025;97:e70258.
    PubMed         Abstract available

  14. KIM J, Han E, Kim J, Kim YJ, et al
    Comparative Evaluation of the PowerChek Respiratory Virus Panel RT-PCR Assay Detecting 16 Respiratory Viruses Including SARS-CoV-2.
    J Med Virol. 2025;97:e70243.
    PubMed         Abstract available

  15. ZHAO Y, He C, Peng M, Li M, et al
    Large-Scale Screening of CD4(+) T-Cell Epitopes From SARS-CoV-2 Proteins and the Universal Detection of SARS-CoV-2 Specific T Cells for Northeast Asian Population.
    J Med Virol. 2025;97:e70241.
    PubMed         Abstract available

  16. HO SY, Zhou YT, Ho SY, Hu YL, et al
    Clinical Characteristics and Severity Predictors of Pediatric Adenovirus Infections.
    J Med Virol. 2025;97:e70248.
    PubMed         Abstract available

  17. HOTA M, Wondeu ALD, Abakar MF, Dezoumbe K, et al
    Integrated Seroprevalence and Genome-Based Study of SARS-CoV-2 Viral Strains in N'Djamena: Insights Into Chad's COVID-19 Epicenter.
    J Med Virol. 2025;97:e70234.
    PubMed         Abstract available

  18. DAMODAR T, Pattabiraman C, Singh B, Jose M, et al
    Microbiological Investigations for Chikungunya Virus in Children With Acute Encephalitis Syndrome in a Non-Outbreak Setting in Southern India.
    J Med Virol. 2025;97:e70233.
    PubMed         Abstract available


    J Virol

  19. SOULTSIOTI M, de Jong AWM, Blomberg N, Tas A, et al
    Perturbation of de novo lipogenesis hinders MERS-CoV assembly and release, but not the biogenesis of viral replication organelles.
    J Virol. 2025 Feb 20:e0228224. doi: 10.1128/jvi.02282.
    PubMed         Abstract available


    Lancet Infect Dis

  20. KRAMMER F, Barclay WS, Beer M, Brown IH, et al
    Europe needs a sustainably funded influenza research and response network.
    Lancet Infect Dis. 2025 Feb 17:S1473-3099(25)00068.
    PubMed        


    N Engl J Med

  21. BROWN JR, Seymour JF, Jurczak W, Aw A, et al
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;392:748-762.
    PubMed         Abstract available


    Nature

  22. MARR LC
    Researchers overlooked airborne diseases for centuries - then COVID-19 changed everything.
    Nature. 2025;638:607-608.
    PubMed        


  23. Learn COVID pandemic lessons - before it's too late.
    Nature. 2025 Feb 18. doi: 10.1038/d41586-025-00498.
    PubMed        

  24. MALLAPATY S
    What sparked the COVID pandemic? Mounting evidence points to raccoon dogs.
    Nature. 2025 Feb 21. doi: 10.1038/d41586-025-00426.
    PubMed        


    Radiology

  25. NARAYAN AK, Foster N, Kadom N, Scott JA, et al
    Six Steps to Improving Health Equity Using Quality Improvement and Patient Safety Tools.
    Radiology. 2025;314:e232750.
    PubMed         Abstract available


    Science

  26. ZASLAVSKY ME, Craig E, Michuda JK, Sehgal N, et al
    Disease diagnostics using machine learning of B cell and T cell receptor sequences.
    Science. 2025;387:eadp2407.
    PubMed         Abstract available


    Travel Med Infect Dis

  27. FLOREZ L, Echeverri-De la Hoz D, Calderon A, Serrano-Coll H, et al
    Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants.
    Travel Med Infect Dis. 2025;64:102820.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Feb. 23 '25)

 


    Antiviral Res

  1. SCHREIBER A, Ludwig S
    Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?
    Antiviral Res. 2025;235:106101.
    PubMed         Abstract available

  2. WU Q, Wu H, Hu Y, Zheng X, et al
    Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
    Antiviral Res. 2025 Jan 24:106092. doi: 10.1016/j.antiviral.2025.106092.
    PubMed         Abstract available

  3. XU M, Zhang Z, Sun Y, Mai H, et al
    IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility.
    Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082.
    PubMed         Abstract available


    Biochemistry

  4. LEE S, Yan S, Dey A, Laederach A, et al
    A Cascade of Conformational Switches in SARS-CoV-2 Frameshifting: Coregulation by Upstream and Downstream Elements.
    Biochemistry. 2025;64:953-966.
    PubMed         Abstract available

  5. DHAKA P, Singh A, Nehul S, Choudhary S, et al
    Disruption of Molecular Interactions between the G3BP1 Stress Granule Host Protein and the Nucleocapsid (NTD-N) Protein Impedes SARS-CoV-2 Virus Replication.
    Biochemistry. 2025;64:823-840.
    PubMed         Abstract available


    Cell

  6. WANG E, Cohen AA, Caldera LF, Keeffe JR, et al
    Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.
    Cell. 2025;188:1036-1050.
    PubMed         Abstract available


    Drug Saf

  7. NAMBASA VP, Gunter HM, Adeyemo MB, Bhawaneedin NY, et al
    Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group.
    Drug Saf. 2025;48:233-249.
    PubMed         Abstract available

  8. BOULEFAA D, Bagheri H, Salvo F, Rabier MB, et al
    Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Drug Saf. 2025;48:251-263.
    PubMed         Abstract available


    Epidemiol Infect

  9. SIMMS I, Charlett A, Colon-Gonzalez FJ, Blomquist PB, et al
    Adapting the Flexible Farrington Algorithm for daily situational awareness and alert system to support public health decision-making during the SARS-CoV-2 epidemic in England.
    Epidemiol Infect. 2025;153:e28.
    PubMed         Abstract available

  10. HAYES J, Lee SS, Carnevale J, Shamir D, et al
    Performance and functional assessment of the Kimera P-IV point-of-care plasmonic qPCR prototype for ultra rapid pathogen detection of chlamydia trachomatis.
    Epidemiol Infect. 2025;153:e27.
    PubMed         Abstract available


    J Infect

  11. MONK EJM, Foulkes S, Munro K, Atti A, et al
    Characterisation of the SARS-CoV-2 pandemic in healthcare workers within the United Kingdom: risk factors for infection during four successive waves.
    J Infect. 2024 Dec 27:106393. doi: 10.1016/j.jinf.2024.106393.
    PubMed         Abstract available

  12. MENSAH AA, Stowe J, Brown K, LopezBernal J, et al
    COVID-19 reinfection in pregnancy: assessment of Severity and pregnancy outcomes in England.
    J Infect. 2024 Dec 27:106392. doi: 10.1016/j.jinf.2024.106392.
    PubMed         Abstract available

  13. RUBIO R, Yavlinsky A, Zamudio ME, Molinos-Albert LM, et al
    Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.
    J Infect. 2024 Dec 31:106402. doi: 10.1016/j.jinf.2024.106402.
    PubMed         Abstract available

  14. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    PubMed         Abstract available

  15. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    PubMed         Abstract available

  16. NURMI V, Mayne R, Knight C, Almonacid-Mendoza HL, et al
    Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial.
    J Infect. 2025 Jan 9:106412. doi: 10.1016/j.jinf.2025.106412.
    PubMed         Abstract available

  17. WENDEL-GARCIA PD, Ceccato A, Motos A, Franch-Llasat D, et al
    Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study.
    J Infect. 2025 Jan 13:106411. doi: 10.1016/j.jinf.2025.106411.
    PubMed         Abstract available

  18. ROMERO-RAMIREZ A, Somasundaran A, Kontogianni K, Parkes J, et al
    Evaluation of the diagnostic accuracy of Xpert(R) Mpox and STANDARD M10 MPX/OPX for the detection of monkeypox virus.
    J Infect. 2025 Jan 15:106413. doi: 10.1016/j.jinf.2025.106413.
    PubMed         Abstract available

  19. FENG S, Bibi S, Aley PK, Cappuccini F, et al
    Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
    J Infect. 2025;90:106423.
    PubMed         Abstract available

  20. BENNETT C, Chau G, Clayton E, Chu L, et al
    Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
    J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428.
    PubMed         Abstract available

  21. WILLIAMS KV, Krauland MG, Nowalk MP, Harrison LH, et al
    Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling study.
    J Infect. 2025;90:106443.
    PubMed         Abstract available


    J Infect Dis

  22. LEVENE RE, DeVincenzo J, Conery AL, Ahmad A, et al
    EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.
    J Infect Dis. 2025;231:e290-e298.
    PubMed         Abstract available

  23. MAVIAN CN, Tagliamonte MS, Bassett M, Alam M, et al
    COVID-19 lineages in a minimally vaccinated island population: Genomic epidemiology of SARS-CoV-2 in Haiti.
    J Infect Dis. 2024 Oct 23:jiae520. doi: 10.1093.
    PubMed         Abstract available

  24. HAGER DN, Zhu Y, Sohn I, Stubblefield WB, et al
    Effectiveness of the original monovalent mRNA COVID-19 vaccination series against hospitalization for COVID-19-associated venous thromboembolism.
    J Infect Dis. 2024 Oct 15:jiae502. doi: 10.1093.
    PubMed         Abstract available

  25. KANG HM, Kim HJ, Jung J, Ahn JY, et al
    Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent Vaccine in the Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational Study.
    J Infect Dis. 2024 Nov 29:jiae536. doi: 10.1093.
    PubMed         Abstract available


  26. Correction to: An Update on Highly Pathogenic Avian Influenza A(H5N1) Virus, Clade 2.3.4.4b.
    J Infect Dis. 2025 Feb 17:jiaf085. doi: 10.1093.
    PubMed        


    J Virol Methods

  27. FRAISSE A, Guillier L, Cordevant C, Le Poder S, et al
    Impedance-based method for the quantification of infectious SARS-CoV-2.
    J Virol Methods. 2025;333:115110.
    PubMed         Abstract available

  28. HOFF K, Ding X, Liu XL, Lin JY, et al
    Rapid, inexpensive multiplex pathogen detection using resequencing microarrays.
    J Virol Methods. 2025;333:115109.
    PubMed         Abstract available

  29. NGUYEN MA, Williams C, Gard AL, Connor JH, et al
    Endothelial growth media components alter SARS-CoV-2 spike-directed growth kinetics.
    J Virol Methods. 2025;333:115111.
    PubMed         Abstract available

  30. IBRAHIM S, Spackman E, Suarez DL, Goraichuk IV, et al
    Evaluation of an N1 NA antibody-specific enzyme-linked lectin assay for detection of H5N1 highly pathogenic avian influenza virus infection in vaccinated birds.
    J Virol Methods. 2025 Feb 14:115127. doi: 10.1016/j.jviromet.2025.115127.
    PubMed         Abstract available

  31. LOPEZ KP, Cool KR, Bold D, Gaudreault NN, et al
    Detection of SARS-CoV-2- specific antibodies in domestic cats using different ELISA tests.
    J Virol Methods. 2025;333:115099.
    PubMed         Abstract available


    Minerva Pediatr (Torino)

  32. GIALLONARDO M, Uccella S, De Carli F, Nobili L, et al
    Stress symptoms and Coronavirus disease 2019 (COVID-19): a comparative study between Attention Deficit Hyperactivity Disorder and typically developing children and adolescents.
    Minerva Pediatr (Torino). 2025;77:62-67.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  33. NARAHARISETTI R, Weinberg M, Stoddard B, Stobierski MG, et al
    Highly Pathogenic Avian Influenza A(H5N1) Virus Infection of Indoor Domestic Cats Within Dairy Industry Worker Households - Michigan, May 2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:61-65.
    PubMed         Abstract available


    PLoS Comput Biol

  34. GAO S, Chakraborty AK, Greiner R, Lewis MA, et al
    Early detection of disease outbreaks and non-outbreaks using incidence data: A framework using feature-based time series classification and machine learning.
    PLoS Comput Biol. 2025;21:e1012782.
    PubMed         Abstract available

  35. SHEN X, Rumack A, Wilder B, Tibshirani RJ, et al
    Nowcasting reported covid-19 hospitalizations using de-identified, aggregated medical insurance claims data.
    PLoS Comput Biol. 2025;21:e1012717.
    PubMed         Abstract available


    PLoS One

  36. LI J, Tao L, Zhou Y, Zhu Y, et al
    Identification of biomarkers in Alzheimer's disease and COVID-19 by bioinformatics combining single-cell data analysis and machine learning algorithms.
    PLoS One. 2025;20:e0317915.
    PubMed         Abstract available

  37. IMTIAZ K, Farooqui N, Ahmed K, Zhamalbekova A, et al
    Analysis of differential expression of matrix metalloproteinases and defensins in the nasopharyngeal milieu of mild and severe COVID-19 cases.
    PLoS One. 2025;20:e0304311.
    PubMed         Abstract available

  38. OYASU A, Salter-Volz A, Yeh C, Muhammad LN, et al
    Evaluating Covid-19 publications for sex and gender-specific health content: A bibliometric analysis.
    PLoS One. 2025;20:e0316812.
    PubMed         Abstract available

  39. HUANG X, Gao Q, Wang D
    The impact of top management team tenure heterogeneity on innovation efficiency of declining firms.
    PLoS One. 2025;20:e0313624.
    PubMed         Abstract available

  40. WANDER PL, Lowy E, Korpak A, Beste LA, et al
    SARS-CoV-2 infection is associated with higher chance of diabetes remission among Veterans with incident diabetes.
    PLoS One. 2025;20:e0317348.
    PubMed         Abstract available

  41. GALAL N, Beshay BY, Soliman O, Ismail MI, et al
    Evaluating the structure-based virtual screening performance of SARS-CoV-2 main protease: A benchmarking approach and a multistage screening example against the wild-type and Omicron variants.
    PLoS One. 2025;20:e0318712.
    PubMed         Abstract available

  42. MCCONNELL J, Rushton A, Noblet T, Pacey V, et al
    Perceptions, experiences, barriers, facilitators, learning outcomes, and modes of assessment of digital clinical placements for pre-registration physiotherapy students internationally: a systematic review protocol.
    PLoS One. 2025;20:e0319024.
    PubMed         Abstract available

  43. VASHI B, Pettrone K, Wilson CS, Chenoweth JG, et al
    COVID-19 symptom severity and duration among outpatients, July 2021-May 2023: The PROTECT observational study.
    PLoS One. 2025;20:e0314518.
    PubMed         Abstract available

  44. PANAZAN O, Gheorghe C
    Impact of geopolitical risks and innovation on global defense stock return.
    PLoS One. 2025;20:e0312155.
    PubMed         Abstract available

  45. DARJANA D, Wiyono SK, Koesrindartoto DP
    Research on the impact of COVID-19 on the financial system: Evidence from Indonesia.
    PLoS One. 2025;20:e0301123.
    PubMed         Abstract available

  46. SHI H, Zhang X, Ross TM
    A single dose of inactivated influenza virus vaccine expressing COBRA hemagglutinin elicits broadly-reactive and long-lasting protection.
    PLoS One. 2025;20:e0308680.
    PubMed         Abstract available

  47. IRGENS MS, O'Neill RM, Ruiz JM
    Multi-level quality assessment of United States COVID-19 epidemiological surveillance.
    PLoS One. 2025;20:e0319263.
    PubMed         Abstract available

  48. SODHI S, Chamali R, Praveen D, Sharma M, et al
    Does integration matter? an international cross-sectional study on the relationship between perceived public health and primary care integration and COVID-19 vaccination rates.
    PLoS One. 2025;20:e0317970.
    PubMed         Abstract available

  49. HWANG SH, Chang Y, Bai H, Yun J, et al
    Impact of COVID-19 on admission and in-hospital mortality of patients with acute myocardial infarction in Korea: An interrupted time series analysis.
    PLoS One. 2025;20:e0316943.
    PubMed         Abstract available

  50. SENTIEIRO ML, Cunha Ferreira L, Pires de Miranda M, Araujo Vitoria B, et al
    Couples and parenting dynamics during Covid-19 pandemic: A systematic review of the literature.
    PLoS One. 2025;20:e0315417.
    PubMed         Abstract available

  51. AZI LMTA, Ferreira TS, Cerqueira-Silva T, Diego LAS, et al
    Prevalence of burnout syndrome in Brazilian anesthesiologists during the COVID-19 pandemic: A cross-sectional survey.
    PLoS One. 2025;20:e0313538.
    PubMed         Abstract available

  52. TIMONEDA JC, Vera SV
    Behind the mask: Random and selective masking in transformer models applied to specialized social science texts.
    PLoS One. 2025;20:e0318421.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  53. GONZALES JE 2ND, Kim I, Bastiray A, Hwang W, et al
    Evolutionary rewiring of the dynamic network underpinning allosteric epistasis in NS1 of the influenza A virus.
    Proc Natl Acad Sci U S A. 2025;122:e2410813122.
    PubMed         Abstract available


    Vaccine

  54. ZHANG Y, Li X, Yang Y, Yin Y, et al
    Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
    Vaccine. 2025;48:126722.
    PubMed         Abstract available

  55. DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al
    Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
    Vaccine. 2025;48:126727.
    PubMed         Abstract available

  56. DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al
    The impact of vaccination on the length of stay of hospitalized COVID-19 patients in Brazil.
    Vaccine. 2025;48:126735.
    PubMed         Abstract available

  57. SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al
    Childhood opportunity index and vaccine uptake in pediatric COVID-19 hospitalizations.
    Vaccine. 2025;48:126734.
    PubMed         Abstract available

  58. RAINERI D, Mazzucca CB, Moia R, Bruna R, et al
    Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination.
    Vaccine. 2025;48:126723.
    PubMed         Abstract available

  59. PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al
    The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
    Vaccine. 2025;48:126725.
    PubMed         Abstract available

  60. ADU P, Popoola T, Iqbal N, Roemer A, et al
    A cross-country network analysis of disease infodemics: Looking through the lens of the COVID-19 pandemic.
    Vaccine. 2025;48:126733.
    PubMed         Abstract available

  61. OKA E, Ueda Y, Yagi A, Machida M, et al
    Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
    Vaccine. 2025;48:126767.
    PubMed         Abstract available

  62. WANG B, Lassi Z, Andraweera P, Chen G, et al
    Pregnant women's choices for preventing respiratory syncytial virus (RSV).
    Vaccine. 2025;48:126790.
    PubMed         Abstract available

  63. MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al
    A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
    Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768.
    PubMed         Abstract available

  64. CHANG C, Patel H, Ferrari A, Scalzo T, et al
    sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.
    Vaccine. 2025;51:126883.
    PubMed         Abstract available

  65. APPEL AM, Janbek J, Laursen TM, Gasse C, et al
    Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults.
    Vaccine. 2025;51:126864.
    PubMed         Abstract available

  66. TAAFFE J, Goldin S, Lambach P, Sparrow E, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2023.
    Vaccine. 2025;51:126839.
    PubMed         Abstract available

  67. ZHAO T, Liu X, Huang X, Wang L, et al
    Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice.
    Vaccine. 2025;51:126882.
    PubMed         Abstract available


    Virus Res

  68. GHAMMAZ H, Melloul M, Mbarki A, Hemlali M, et al
    Genomic evolution of SARS-CoV-2 in Morocco: Insights from whole genome sequences collected from 2020 to 2024.
    Virus Res. 2025;353:199530.
    PubMed         Abstract available

#Genomics of novel #influenza A virus (#H18N12) in #bats, Caribe #Colombia

Abstract

Influenza viruses are highly capable of mutating and adapting in mammalian hosts. While these viruses have been extensively studied in birds, research on their presence in bats has been limited. However, influenza viruses circulating in bats have shown notable molecular divergence. The present study aimed to characterize the phylogenetic, evolutionary, and antigenic relationships of an influenza A virus detected in the fishing bat Noctilio albiventris. As part of a pathogen surveillance study of public health interest, 159 rectal samples were collected from bats in the Colombian Caribbean. The samples were sequenced using RNA-Seq. A genome (eight viral contigs) associated with the Orthomyxoviridae family was identified in a pool. Most segments showed approximately 90% similarity with H18N11, except for the neuraminidase. Analysis of the N protein shows that occupies a basal position relative to the N11 subtype, with its divergence date estimated to be approximately 50 years earlier than the earliest reported N11 sequence. 3D modeling identified three mutations (K363R, T242K, and I139V), which may enhance interaction with the HLA-DR of bats. The analyses and antigenic divergence observed in the N protein of N. albiventris suggests the existence of a new subtype (H18N12) with unknown pathogenicity, which requires further investigation.

Source: Scientific Reports, https://www.nature.com/articles/s41598-025-91026-8

____

A #framework for #tracking global #progress on #preparedness for #respiratory #pandemics

{Summary}

1 Introduction

The COVID-19 pandemic underscored the urgency of ensuring that the world is prepared for the next major respiratory pathogen pandemic (1). Corresponding with World Health Assembly resolutions WHA58.5 (2) and WHA74.7 (3), WHO is committed to supporting Member States with pandemic preparedness planning through the provision of guidance and technical assistance. Following on from the PRET Global Meeting in April 2023, WHO has finalized guidance on Preparedness and resilience for emerging threats (PRET) module (1): planning for respiratory pathogen pandemics. This module acknowledges that similar systems and capacities can be used to prevent, prepare for and respond to different respiratory pathogens. The module (4) has three overarching objectives:

- to guide countries and partners in developing or updating their integrated approach to respiratory pathogen pandemic preparedness for equitable and robust response;

- to focus attention on the actions needed to strengthen respiratory pathogen pandemic preparedness functionally, in line with the International Health Regulations (IHR 2005) core capacities; and

- to provide an organizing framework, pragmatic steps and an outline to structure pandemic preparedness and response planning.

A framework is needed to support and analyse respiratory pathogen pandemic preparedness globally through the lens of PRET.

The International Health Regulations (IHR) Monitoring and Evaluation Framework (5) offers several resources and tools that can be used to assess national core capacities for public health emergencies. To complement this cross-cutting framework, a framework for tracking global progress on respiratory pathogen pandemic preparedness is needed to focus on hazard-relevant capacities. Drawing on lessons from the coronavirus disease 2019 (COVID-19) pandemic, it is critical to routinely look at the status of the world’s functional capacities to prevent, prepare and respond to a respiratory pathogen pandemic.

Strengthening overall capacity for health emergency prevention, preparedness response and resilience (HEPR) calls for strengthening five core health emergency components, including: emergency coordination, collaborative surveillance, community protection, clinical care, and access to countermeasures (6). Accordingly, this Framework will support WHO, countries and partners in monitoring progress, identifying gaps and undertaking necessary course corrections across these five areas, helping us to better prepare for a future respiratory pathogen pandemic.

At the time of the next respiratory pathogen pandemic, a framework to monitor pandemic response actions will need to be established in line with the specific context and operational needs.


Objectives

This Framework serves as a tool to track global progress in preparing for future respiratory pathogen pandemics. Its objectives are threefold:

-- to provide a global snapshot on the status of capacities that support preparedness for respiratory pathogen pandemics; y to inform strategic actions and operational decisions for support of respiratory pathogen pandemic planning; and 

-- to stimulate continuous improvement, including course corrections, in respiratory pathogen pandemic planning and preparedness strengthening.

This Framework is primarily intended to reflect preparedness at the global and regional levels, both to track progress and to identify gaps across the five capacity areas of health emergency preparedness. It is not intended to be used for inter- or intraregional comparisons, nor is it intended to be used as a comprehensive national level monitoring framework.


Target audience

This Framework is intended to be used by stakeholders involved in implementing and monitoring respiratory pathogen pandemic preparedness. At the global and regional levels, this includes and is not limited to WHO and other United Nations organizations, international and intergovernmental agencies, nongovernmental organizations, civil society organizations, philanthropic institutions, funding institutions and academia.

While the Framework is not directly intended to be a comprehensive national level tool, stakeholders at the country level may find it useful to contextualize discussions on and/or revisions to national monitoring methods. Interested parties at the country level may include ministries of health and other government agencies as well as cross-sectoral public and private partners, civil society groups, academics, and subnational stakeholders involved in preventing, preparing, and responding to pandemics.


Scope

This Framework interfaces with other preparedness and response frameworks, such as those linked to IHR 2005, to maintain coherence in global monitoring. While the IHR looks at system and capacity preparedness for all health emergencies, this Framework focuses on indicators that reflect preparedness specifically for respiratory pathogen pandemics. This Framework is not intended to comprehensively monitor all relevant technical areas, but rather to give a “snapshot” of the state of global preparedness.

The Framework is organized according to the five HEPR components, namely capacities for: emergency coordination, collaborative surveillance, community protection, clinical care, and access to countermeasures. In alignment with both the IHR 2005 and HEPR frameworks, this Framework consists of a targeted list of indicators that primarily reflect functional capacities of preparedness for respiratory pathogen pandemics.

The indicators included in the Framework have primarily been selected from pre-existing sources – as described in the chapter on methodology – to avoid duplication of efforts and to maximize the feasibility and stability of the monitoring system. The selection criteria for indicators include:

-- reflective of preparedness for respiratory pathogen pandemics;

-- representative of functional, dynamic capacities;

-- has an established data source; and

-- applicable to all WHO Member States.

While the intent is for indicators to focus on respiratory-specific elements, this was not always possible. In cases where respiratory-specific indicators were not available, broader health emergency preparedness proxy indicators have been selected to represent the capacity area. Annex 1 presents an overview of the process of indicator selection.

A few indicators identified as being under development may serve as additional facets of respiratory preparedness. Accordingly, Annex 2 captures potential global indicators that may be monitored in the future, although the data for these indicators are not currently being collected in any standardized manner.


Approach

Preparedness for respiratory pathogen pandemics will be monitored using both quantitative and qualitative approaches. These include through indicators listed in this Framework, as well as through case studies and reviews of implementation collected through a variety of forums. A synthesis of the overall state of preparedness will be summarized and made available through yearly progress reports. This Framework will be in effect from 2024 until 2030. It will be subject to revision over time according to critical needs and to incorporate new respiratory-focused indicators that fit the inclusion criteria and have an established data reporting mechanism. The approach is summarized below:

-- monitoring methods:

- indicators (quantitative)

- country examples (qualitative)

- reporting methods:

- annual progress report

- relevant dashboards

- stakeholder meetings.

(...)

Source: ReliefWeb, https://reliefweb.int/report/world/framework-tracking-global-progress-preparedness-respiratory-pandemics

Original Document: World Health Organization, https://www.who.int/publications/i/item/9789240094246

____

My New Space

Most Popular Posts